Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model

Multiple sclerosis (MS) is an inflammatory autoimmune disease affecting the central nervous system (CNS) that currently does not have any effective treatment. Experimental autoimmune encephalomyelitis (EAE) is often employed as a model to mimic the clinical manifestations of MS, mainly CNS demyelina...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Frontiers in Molecular Neuroscience
المؤلفون الرئيسيون:	Rong Chen, Xing Cao, Wenxiu Luo, Haodi Yang, Xinya Luo, Juming Yu, Jiaming Luo
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2020-06-01
الموضوعات:	multiple sclerosis experimental autoimmune encephalomyelitis dabigatran protease-activated receptors sphingosine-1-phosphate coagulation
الوصول للمادة أونلاين:	https://www.frontiersin.org/article/10.3389/fnmol.2020.00114/full

مواد مشابهة

Role of SphK/S1P in cardiovascular diseases
حسب: TANG Lihong, CHEN Chunling
منشور في: (2024-08-01)

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
حسب: Weiwei Shi, وآخرون
منشور في: (2020-06-01)

SphK1‐driven autophagy potentiates focal adhesion paxillin‐mediated metastasis in colorectal cancer
حسب: Jiang‐Ni Wu, وآخرون
منشور في: (2021-09-01)

The SphK1/S1P axis regulates morphology and cell-cell interactions of retina pigment epithelium cells
حسب: Camila Torlaschi, وآخرون
منشور في: (2025-09-01)

Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
حسب: Masato Komai, وآخرون
منشور في: (2024-03-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
حسب: Jong-Min Kim, وآخرون
منشور في: (2022-01-01)

Resveratrol Inhibits Lipopolysaccharide-Induced Extracellular Matrix Accumulation and Inflammation in Rat Glomerular Mesangial Cells by SphK1/S1P2/NF-κB Pathway
حسب: Gong W, وآخرون
منشور في: (2020-11-01)

Syntheses of Hydrazino-and Azo-Sphingosine Derivatives and Their Evaluation as SphK Inhibitors
حسب: Yolanda Díaz, وآخرون
منشور في: (2019-09-01)

Leucine-rich Repeats and Immunoglobulin 1 (LRIG1) Ameliorates Liver Fibrosis and Hepatic Stellate Cell Activation via Inhibiting Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P) Pathway
حسب: Wei Zhan, وآخرون
منشور في: (2020-08-01)

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran
حسب: Jong-Min Kim, وآخرون
منشور في: (2025-07-01)

Thrombin Contributes to Anti-myeloperoxidase Antibody Positive IgG-Mediated Glomerular Endothelial Cells Activation Through SphK1-S1P-S1PR3 Signaling
حسب: Xiao-Jing Sun, وآخرون
منشور في: (2019-02-01)

Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis
حسب: Xin Tracy Liu, وآخرون
منشور في: (2024-01-01)

Ozanimod-mediated remission in experimental autoimmune encephalomyelitis is associated with enhanced activity of CNS CD27low/- NK cell subset
حسب: Doua Kamyan, وآخرون
منشور في: (2024-03-01)

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib
حسب: Jing Zhang, وآخرون
منشور في: (2025-01-01)

The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis
حسب: S. P. Abdullaev, وآخرون
منشور في: (2020-11-01)

Mechanisms and potential therapeutic targets of SphK1 and SphK2 in hepatocellular carcinoma
حسب: XiaoYing Xu, وآخرون
منشور في: (2025-10-01)

Pharmacokinetics and Pharmacogenetics of Dabigatran
حسب: A. V. Savinova, وآخرون
منشور في: (2021-03-01)

Urticarial Vasculitis Associated with Dabigatran
حسب: Elisa Macedo Brás, وآخرون
منشور في: (2024-10-01)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
حسب: Pancras C. Wong, وآخرون
منشور في: (2021-05-01)

DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY
حسب: N. A. Novikova, وآخرون
منشور في: (2019-06-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
حسب: Esme Ekizoğlu
منشور في: (2018-06-01)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
حسب: Hyewon Chung, وآخرون
منشور في: (2023-02-01)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
حسب: Sié P
منشور في: (2016-05-01)

Pharmacological basis and clinical evidence of dabigatran therapy
حسب: Redondo Santiago, وآخرون
منشور في: (2011-12-01)

IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE
حسب: Olga O. Shakhmatova
منشور في: (2018-12-01)

Dabigatran Kullanımına Sekonder Nadir Görülen Ciddi Koagülopati
حسب: Ecem Sevim, وآخرون
منشور في: (2022-06-01)

UGT2B15 single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans
حسب: Jin-Woo Park, وآخرون
منشور في: (2025-01-01)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
حسب: S. V. Moiseev
منشور في: (2015-12-01)

A dangerous adverse event in the use of dabigatran
حسب: Manuel Monti, وآخرون
منشور في: (2015-11-01)

Sphk1 regulates HMGB1 via HDAC4 and mediates epithelial pyroptosis in allergic rhinitis
حسب: Wei Huang, MM, وآخرون
منشور في: (2024-09-01)

Dabigatran and Dental Procedures in Patients with High Risk Bleeding
حسب: Hossien Akbari, وآخرون
منشور في: (2024-01-01)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
حسب: Jameel Abdulrehman, وآخرون
منشور في: (2021-07-01)

Electrochemical Disposable Biosensor to Monitor Dabigatran in Point-of-Care Anticoagulation Therapy
حسب: Ashwin K. V. Mruthunjaya, وآخرون
منشور في: (2023-06-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
حسب: İrfan Aydın, وآخرون
منشور في: (2020-03-01)

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
حسب: Zhu Zhu, وآخرون
منشور في: (2022-11-01)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
حسب: Yin Lu, وآخرون
منشور في: (2022-01-01)

Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population
حسب: Ayan Abdrakhmanov, وآخرون
منشور في: (2024-05-01)

Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
حسب: Jhih-Wei Dai, وآخرون
منشور في: (2023-05-01)

Intraperitoneal Hemorrhage in a Peritoneal Dialysis Patient Using Dabigatran: A Case Report
حسب: Egemen Cebeci, وآخرون
منشور في: (2016-06-01)

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
حسب: Valentin Held, وآخرون
منشور في: (2016-10-01)